Table 1.
Association between expression level of GPR155 mRNA and clinicopathological parameters in 144 patients with hepatocellular carcinoma
| Clinicopathological parameters | Downregulation of GPR155
(n = 57) |
Others (n = 87) |
p value |
|---|---|---|---|
| Age | 0.349 | ||
| < 65 year | 23 | 42 | |
| ≥ 65 year | 34 | 45 | |
| Gender | 0.013* | ||
| Female | 4 | 19 | |
| Male | 53 | 68 | |
| Background liver | 0.188 | ||
| Normal liver | 2 | 8 | |
| Chronic hepatitis | 37 | 45 | |
| Cirrhosis | 18 | 34 | |
| Pugh-Child’s classification | 0.044* | ||
| A | 50 | 84 | |
| B | 7 | 3 | |
| Hepatitis virus | 0.757 | ||
| Absent | 9 | 18 | |
| HBV | 15 | 22 | |
| HCV | 33 | 47 | |
| AFP (ng/ml) | 0.002* | ||
| ≤ 20 | 22 | 56 | |
| > 20 | 35 | 31 | |
| PIVKA II (mAU/ml) | 0.002* | ||
| ≤ 40 | 14 | 44 | |
| > 40 | 43 | 43 | |
| Tumor multiplicity | 0.078 | ||
| Solitary | 40 | 72 | |
| Multiple | 17 | 15 | |
| Tumor size | 0.120 | ||
| < 3.0 cm | 14 | 32 | |
| ≥ 3.0 cm | 43 | 55 | |
| Differentiation | 0.009* | ||
| Well | 7 | 28 | |
| Moderate | 43 | 55 | |
| Poor | 7 | 4 | |
| Growth type | 0.495 | ||
| Expansive growth | 46 | 74 | |
| Invasive growth | 11 | 13 | |
| Serosal infiltration | 0.031* | ||
| Absent | 49 | 60 | |
| Present | 23 | 12 | |
| Formation of capsule | <0.001* | ||
| Absent | 33 | 76 | |
| Present | 24 | 11 | |
| Infiltration to capsule | 0.035* | ||
| Absent | 20 | 46 | |
| Present | 37 | 41 | |
| Septum formation | 0.036* | ||
| Absent | 14 | 36 | |
| Present | 43 | 51 | |
| Vascular invasion | <0.001* | ||
| Absent | 34 | 74 | |
| Present | 23 | 13 | |
| UICC pathological stage | <0.001* | ||
| I | 25 | 65 | |
| II | 22 | 15 | |
| III | 10 | 7 | |
Abbreviations: HBV hepatitis B virus, HCV hepatitis C virus, AFP α-fetoprotein, PIVKA protein induced by vitamin K antagonists, UICC Union for International Cancer Control. *Statistically significant difference (p < 0.05)